Syros Pharmaceuticals - Bathi sing dikarepake SYRS

Syros Pharmaceuticals (SYRS) relies on a lean R&D model by outsourcing substance synthesis to external contractors. This consensus earnings forecast chart reflects market expectations, where the figure is fixed at . A patent shield on biomarkers serves as a defensive asset, although there is currently no cash flow as the development of genetic platforms remains in the clinical trial stage.
Syros (SYRS) - rincian metrik lan laporan keuangan

This indicator reflects the dynamics of expected net income, allowing for the differentiation between a market correction and a fundamental devaluation of the business. Analysis of the planned profit trend reveals the company's resilience to external shocks through the stability of daily calculations. The metric measures the probability of capitalization recovery, signaling margin degradation during a prolonged decline. For Syros Pharmaceuticals (SYRS), this confirms the effectiveness of its scientific portfolio management. Prudent capital expenditure on genetic control in oncology minimizes the risk of a long-term investment freeze.